{
    "root": "c6e20031-cb11-4a7d-80d0-5dceee919da0",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "PADCEV",
        "suffix": {
            "text": "EJFV"
        }
    },
    "value": "20250228",
    "ingredients": [
        {
            "name": "ENFORTUMAB VEDOTIN",
            "code": "DLE8519RWM"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE",
            "code": "X573657P6P"
        },
        {
            "name": "TREHALOSE DIHYDRATE",
            "code": "7YIN7J07X4"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH"
        }
    ],
    "indications": "PADCEV®, in combination with pembrolizumab, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC).\n                  PADCEV, as a single agent, is indicated for the treatment of adult patients with locally advanced or mUC who:\n                  \n                     \n                        •have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or\n                     \n                        •are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.",
    "contraindications": "• For intravenous infusion only. Do not administer PADCEV as an intravenous push or bolus. Do not mix with, or administer as an infusion with, other medicinal products. ( 2.3 ) • The recommended dose of PADCEV in combination with pembrolizumab is 1.25 mg/kg (up to a maximum dose of 125 mg) given as an intravenous infusion over 30 minutes on Days 1 and 8 of a 21-day cycle until disease progression or unacceptable toxicity. ( 2.1 ) • The recommended dose of PADCEV as a single agent is 1.25 mg/kg (up to a maximum dose of 125 mg) given as an intravenous infusion over 30 minutes on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity. ( 2.1 ) • Avoid use in patients with moderate or severe hepatic impairment ( 8.6 )",
    "warningsAndPrecautions": "How Supplied \n                  \n                  PADCEV (enfortumab vedotin-ejfv) 20 mg and 30 mg are supplied as a sterile, preservative-free, white to off-white lyophilized powder in single-dose vials. PADCEV vials are available in the following packages:\n                  \n                     \n                        •Carton of one 20 mg single-dose vial (NDC 51144-020-01)\n                     \n                        •Carton of one 30 mg single-dose vial (NDC 51144-030-01)\n                  \n                  \n                     Storage\n                  \n                  Store PADCEV vials refrigerated at 2ºC to 8ºC (36ºF to 46ºF) in the original carton. Do not freeze. Do not shake.\n                  \n                     Special Handling\n                  \n                  PADCEV is a hazardous drug. Follow applicable special handling and disposal procedures.1",
    "adverseReactions": "None."
}